Hikma launches generic Onfi
Hikma Pharmaceuticals is introducing clobazam oral suspension 2.5mg/mL, and clobazam tablets 10mg and 20mg. The product is the generic of Lundbeck’s Onfi.
Hikma’s clobazam is a benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients age 2 years old and older.
Clobazam oral suspension had a market value of approximately $260 million, and Clobazam tablets had a market value of about $601 million in the 12 months ended September 2018, according to IQVIA data.
“We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio,” Brian Hoffmann, Hikma president of the generics division, said. “This will be among the first generics available on the market, and we are pleased to improve patients' access to this important medicine.”
Hikma’s clobazam is a benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients age 2 years old and older.
Clobazam oral suspension had a market value of approximately $260 million, and Clobazam tablets had a market value of about $601 million in the 12 months ended September 2018, according to IQVIA data.
“We are very excited to add Clobazam oral suspension and Clobazam tablets to our product portfolio,” Brian Hoffmann, Hikma president of the generics division, said. “This will be among the first generics available on the market, and we are pleased to improve patients' access to this important medicine.”